PLRZ Polyrizon Ltd.
Price Chart
Executive Summary
Polyrizon announced submission of amended claims in a U.S. patent application for its intranasal drug delivery platform, expanding IP protection to include drug delivery systems and methods of use. The press release is forward-looking and does not guarantee patent issuance or revenue. The filing is routine IP news with no material financial impact.
Actionable Insight
Monitor for patent office actions and any subsequent licensing or partnership announcements. The patent expansion is a positive IP step but does not change near-term fundamentals. Recent dilutive offering (April 2026) still overhangs the stock.
Key Facts
- Filed amended claims with U.S. Patent Office for intranasal drug delivery platform
- Expanded claims cover mucoadhesive compositions, drug delivery systems, and methods of use
- Platform aims to improve drug residence time, bioavailability, and film formation on mucosal tissues
- Company is a development-stage biotech with no current revenue; relies on future patent protection and commercialization
- No financial data or guidance provided in the filing
Financial Impact
No direct financial impact; patent expansion is an intangible asset development
Risk Factors
- Patent may not be granted; scope of allowed claims uncertain
- No revenue or near-term commercialization expected
- Recent capital raise dilutes existing shareholders
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-051171 |
| Document: ea0288888-6k_polyrizon.htm | 0001213900-26-051171 |
| Document: 0001213900-26-051171-index-headers.html | 0001213900-26-051171 |
| Document: 0001213900-26-051171-index.html | 0001213900-26-051171 |
| Document: 0001213900-26-051171.txt | 0001213900-26-051171 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
6-K
| $12.66 awaiting T+5 | awaiting T+5 | — | $12.52 (−1.07%) |
|
Jun 8, 2026
1d ago
|
Press Release
| $13.22 awaiting T+5 | awaiting T+5 | — | $12.52 (−5.30%) |
|
Jun 5, 2026
4d ago
|
6-K
| $13.22 awaiting T+5 | awaiting T+5 | — | $12.52 (−5.30%) |
|
May 13, 2026
27d ago
|
6-K
| $15.18 $13.98 | ▼ −7.91% | ▼ −6.75% | $12.52 (−17.52%) |
|
May 4, 2026
5w ago
|
6-K
| $15.40 $16.12 | ▲ +4.68% | ▲ +1.74% | $12.52 (−18.70%) |
|
Apr 30, 2026
5w ago
|
F-1/A
| $16.00 $16.34 | ▲ +2.13% | ▼ −0.22% | $12.52 (−21.75%) |
|
Apr 27, 2026
6w ago
|
6-K
| $16.63 $15.40 | ▼ −7.40% | ▼ −7.80% | $12.52 (−24.71%) |
|
Apr 8, 2026
8w ago
|
6-K / PRESS-RELEASE
| $10.75 $10.94 | ▼ −1.77% | ▲ +1.42% | $12.52 (−16.47%) |
|
Apr 8, 2026
8w ago
|
424B5
| $10.75 $10.94 | ▼ −1.77% | ▲ +1.42% | $12.52 (−16.47%) |
|
Mar 30, 2026
10w ago
|
Insider Cluster
| $11.88 $11.08 | ▲ +6.73% | ▲ +11.03% | $12.52 (−5.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access